405 related articles for article (PubMed ID: 31261914)
21. Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.
Liao H; Chen W; Dai Y; Richardson JJ; Guo J; Yuan K; Zeng Y; Xie K
Front Oncol; 2019; 9():883. PubMed ID: 31572677
[TBL] [Abstract][Full Text] [Related]
22. The Janus Face of Tumor Microenvironment Targeted by Immunotherapy.
Buoncervello M; Gabriele L; Toschi E
Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484464
[TBL] [Abstract][Full Text] [Related]
23. Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications.
Zhang W; Liu M; Li W; Song Y
Chin Med J (Engl); 2024 Apr; 137(7):776-790. PubMed ID: 38269619
[TBL] [Abstract][Full Text] [Related]
24. Linking Immunoevasion and Metabolic Reprogramming in B-Cell-Derived Lymphomas.
Böttcher M; Baur R; Stoll A; Mackensen A; Mougiakakos D
Front Oncol; 2020; 10():594782. PubMed ID: 33251150
[TBL] [Abstract][Full Text] [Related]
25. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
26. Lymphomagenesis in Hodgkin lymphoma.
Matsuki E; Younes A
Semin Cancer Biol; 2015 Oct; 34():14-21. PubMed ID: 25725205
[TBL] [Abstract][Full Text] [Related]
27. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory Cells in Diffuse Large B Cell Lymphoma.
Tamma R; Ranieri G; Ingravallo G; Annese T; Oranger A; Gaudio F; Musto P; Specchia G; Ribatti D
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32731512
[TBL] [Abstract][Full Text] [Related]
29. Location, location, location: mapping the lymphoma tumor microenvironment using spatial transcriptomics.
Pickard K; Stephenson E; Mitchell A; Jardine L; Bacon CM
Front Oncol; 2023; 13():1258245. PubMed ID: 37869076
[TBL] [Abstract][Full Text] [Related]
30. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
31. Tumor Microenvironment in T-Cell Lymphomas.
Bennani NN; Ansell SM
Cancer Treat Res; 2019; 176():69-82. PubMed ID: 30596213
[TBL] [Abstract][Full Text] [Related]
32. Lymphomas and Their Microenvironment: A Multifaceted Relationship.
Menter T; Tzankov A
Pathobiology; 2019; 86(5-6):225-236. PubMed ID: 31574515
[TBL] [Abstract][Full Text] [Related]
33. Revisiting Cancer Stem Cells as the Origin of Cancer-Associated Cells in the Tumor Microenvironment: A Hypothetical View from the Potential of iPSCs.
Osman A; Afify SM; Hassan G; Fu X; Seno A; Seno M
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260363
[TBL] [Abstract][Full Text] [Related]
34. Programming the immune checkpoint to treat hematologic malignancies.
Vick E; Mahadevan D
Expert Opin Investig Drugs; 2016 Jul; 25(7):755-70. PubMed ID: 27070269
[TBL] [Abstract][Full Text] [Related]
35. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
Mitteldorf C; Berisha A; Pfaltz MC; Broekaert SMC; Schön MP; Kerl K; Kempf W
Am J Surg Pathol; 2017 Jul; 41(7):998-1004. PubMed ID: 28504999
[TBL] [Abstract][Full Text] [Related]
36. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
Xerri L; Chetaille B; Serriari N; Attias C; Guillaume Y; Arnoulet C; Olive D
Hum Pathol; 2008 Jul; 39(7):1050-8. PubMed ID: 18479731
[TBL] [Abstract][Full Text] [Related]
37. Expression of programmed cell death-ligand 1 in primary testicular diffuse large B cell lymphoma: A retrospective study.
Zhu D; Zhu J; Yu W; Hong P; Fan Y; Zhang Z; Li J; He Q; Han W; Shen C; Jin J
Oncol Lett; 2019 Sep; 18(3):2670-2676. PubMed ID: 31452749
[TBL] [Abstract][Full Text] [Related]
38. Immune targeting of the microenvironment in classical Hodgkin's lymphoma: insights for the hematologist.
Carreau NA; Diefenbach CS
Ther Adv Hematol; 2019; 10():2040620719846451. PubMed ID: 31105921
[TBL] [Abstract][Full Text] [Related]
39. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Tumor Microenvironment of Leukemia and Lymphoma.
Höpken UE; Rehm A
Trends Cancer; 2019 Jun; 5(6):351-364. PubMed ID: 31208697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
